Barclays Maintains Overweight on Omada Health, Lowers Price Target to $22

Benzinga · 5d ago
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $29 to $22.